2022
Transfusion in infants and children
Hendrickson J, Josephson C. Transfusion in infants and children. 2022, 381-391. DOI: 10.1002/9781119719809.ch34.Peer-Reviewed Original ResearchRed blood cell transfusionGraft-versushost diseaseEtiology of anemiaBlood cell transfusionRisk of thrombosisSequestration of plateletsPotential adverse effectsActive bleedingCell transfusionPreterm infantsTransfusion supportCryoprecipitate transfusionOxygen-carrying capacityPediatric patientsPlatelet transfusionsTransfusionFactor VIIIThrombocytopeniaDecreased productionInfantsThawed plasmaAdverse effectsFactor XIIIAcellular productsChildren
2019
Chapter 53 Transfusion Management of Patients Undergoing Hematopoietic Stem Cell and Solid Organ Transplantation
Rutter S, Hendrickson J. Chapter 53 Transfusion Management of Patients Undergoing Hematopoietic Stem Cell and Solid Organ Transplantation. 2019, 337-341. DOI: 10.1016/b978-0-12-813726-0.00053-2.Peer-Reviewed Original ResearchSolid organ transplantationOrgan transplantationHematopoietic stem cellsOptimal transfusion triggerTransfusion adverse eventsBlood product selectionStem cellsGranulocyte transfusionsAdverse eventsPlatelet refractorinessTransfusion supportTransfusion triggerTransfusion managementTransplant servicesRhD typeOptimal outcomesTransfusionPatientsTransplantationCellsRecipientsRefractorinessChapter 57 Platelet Transfusion Refractory Patients
Tormey C, Hendrickson J. Chapter 57 Platelet Transfusion Refractory Patients. 2019, 361-364. DOI: 10.1016/b978-0-12-813726-0.00057-x.ChaptersHuman leukocyte antigenPlatelet refractorinessRefractory patientsPlatelet transfusion-refractory patientsRecipient human leukocyte antigenClass I human leukocyte antigenPlatelet refractory patientsPlatelet transfusion supportManagement of patientsHLA-B antigensCauses of refractorinessHLA alloantibodiesNonimmune causesHost diseaseTransfusion supportLeukocyte antigenOptimal carePatientsClinical teamTransfusion servicesMultidisciplinary approachRefractorinessBlood suppliersPlateletsAntigen
2018
HLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study
Nickel R, Horan J, Abraham A, Qayed M, Haight A, Luban N, Hendrickson J. HLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study. Blood 2018, 132: 3816. DOI: 10.1182/blood-2018-99-114116.Peer-Reviewed Original ResearchBone marrow transplantHLA class ISickle cell diseaseHLA-identical bone marrow transplantsMore platelet transfusionsNon-alloimmunized patientsPlatelet transfusion supportPlatelet transfusionsRBC transfusionClass IPositive PRAPre-BMTTransfusion supportPediatric patientsMarrow transplantCell diseaseBone marrowRed blood cell transfusionHepatic sinusoidal obstruction syndromeApheresis platelet transfusionHLA-disparate donorsBlood cell transfusionSinusoidal obstruction syndromePlatelet transfusion requirementsCord blood grafts
2017
Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation
Hendrickson J, Fasano R. Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation. 2017, 111-136. DOI: 10.1007/978-3-319-62328-3_5.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationSickle cell diseaseRed blood cellsTransfusion supportTransplant physiciansConditioning regimen intensityOptimal transplant outcomesPeri-transplant periodHigher red blood cellStem cell transplantationTransfusion medicine physiciansRegimen intensityUndergoing transplantationPosttransplant periodTransplant outcomesHSCT populationCurative therapyPlatelet transfusionsSCD patientsTransfusion managementCell transplantationTransfusion therapyDonor selectionIron overloadCell disease
2016
Platelet and plasma transfusions for infants and children
Hendrickson J, Josephson C. Platelet and plasma transfusions for infants and children. 2016, 542-548. DOI: 10.1002/9781119013020.ch47.Peer-Reviewed Original ResearchTransfusion supportBlood donor exposuresTransplacental antibody transferEtiology of thrombocytopeniaTreatment of thrombocytopeniaTotal blood volumeMembrane oxygenationExchange transfusionGestational ageABO compatibilityAntibody transferDonor exposureImmature liverBlood volumeThrombocytopeniaMaternal factorsCongenital diseaseCoagulopathyInfantsTransfusionChildrenDiseaseSmall adultsPlateletsSpecial consideration
2015
A Novel Network Analysis Tool to Identify Relationships Between Disease States and Risk for RBC Alloimmunization
Celli R, Schulz W, Hendrickson J, Tormey C. A Novel Network Analysis Tool to Identify Relationships Between Disease States and Risk for RBC Alloimmunization. Blood 2015, 126: 2349. DOI: 10.1182/blood.v126.23.2349.2349.Peer-Reviewed Original ResearchDisease statesControl cohortAcute myeloid leukemia/myelodysplastic syndromeLeukemia/myelodysplastic syndromeRed blood cell alloimmunizationChronic transfusion supportHyper-responder groupAcute renal failureAML/MDSAcute myocardial infarctionICD-9 codesDevelopment of alloantibodiesSpecific medical conditionsElectronic medical recordsSignificant disease associationCertain disease statesAlloimmunized individualsRBC alloimmunizationGastrointestinal bleedPulmonary hypertensionRenal failureTransfusion burdenTransfusion supportMale patientsRBC transfusion